Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emapalumab for macrophage activation syndrome in Still's disease or systemic lupus erythematosus
NL-OMON52297Phase 2Recruiting
- Sponsor
- Recordati SpA
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of emapalumab in macrophage activation syndrome (MAS), systemic juvenile idiopathic arthritis (SJIA), adult-onset Still's disease (AOSD), systemic lupus erythematosus (SLE), sponsored by Recordati SpA. Started Sep 2022; status: recruiting.
02
Drugs
emapalumab
03
Conditions
macrophage activation syndrome (MAS)systemic juvenile idiopathic arthritis (SJIA)adult-onset Still's disease (AOSD)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON52297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52297.